By Annette R. Karnash, R.N., M.N.
New medications called incretin mimetic are currently undergoing clinical trials and may have significant potential impact for a new more effective treatment of diabetes. Incretin minetics are endogenous hormones secreted from the G.I. tract. When food is ingested the G.I. tract secretes an endogenous hormone incretin, which stimulates the secretion of insulin in response to glucose absorption. Two of these hormones, glucose dependent insulinotropic peptide and glucagons – like peptide -1 (GLP-1) have been identified. Aside from increased insulin levels, GLP-1 is thought to also suppress the production of glucagons.
Exenatide is the first incretin mimetic to undergo phase 3 clinical trials. Three studies, 30 weeks long, resulted in a significant reduction in A1C in the patients unable to obtain adequate blood sugar levels with metformin alone or with the addition of a sulfonylurea. The result – the average reduction in A1C over placebo was 1% and improvement in pancreatic beta cell function, while the most common adverse effect was nausea and weight loss. A disadvantage is that the drug is administered only by injection but development is underway to produce a long acting form. Incretin mimetics may likely be an important new therapy category to improve diabetic outcome.